Related Experiment Video
Updated: Jun 7, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Treatment of lupus nephritis
Sebastian Dolff1, Jo Hm Berden, Marc Bijl
1Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands. sebastian.dolff@uk-essen.de
Abstract:
Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations. The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns, which has a crucial impact on the prognosis and treatment options for LN patients. There are widely accepted therapeutic agents available, such as cyclophosphamide, mycophenolate mofetil, azathioprine and corticosteroids. Several trials have tried to determine a gold standard for induction and maintenance therapy in LN, and the place of newer drugs, biologicals, has been investigated. We review recently reported data on current treatment regimens in LN, in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury V: Interprofessional Care
Kidney Transplant II: Surgical Procedure

